<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Bendamustine with or without rituximab provides an effective and more tolerable alternative to the polytherapy <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>-<z:chebi fb="0" ids="28748">doxorubicin</z:chebi>-<z:chebi fb="0" ids="28445">vincristine</z:chebi>-<z:chebi fb="2" ids="8378">prednisolone</z:chebi> (CHOP) in the treatment of haematological <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and is currently approved for the treatment of many <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Navitoclax (<z:chebi fb="5" ids="53329">ABT</z:chebi>-263) is a potent inhibitor of Bcl-2, Bcl-x(L) and Bcl-w, which has demonstrated efficacy in haematological <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> alone and in combination with other agents </plain></SENT>
<SENT sid="2" pm="."><plain>This paper describes the in vivo efficacy of combining either bendamustine or bendamustine plus rituximab (BR) with navitoclax in <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> EXPERIMENTAL APPROACH: Activity was tested in <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DoHH-2, SuDHL-4), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (Granta 519) and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (RAMOS) </plain></SENT>
<SENT sid="3" pm="."><plain>Activity was also monitored in a systemic model of Granta 519 </plain></SENT>
<SENT sid="4" pm="."><plain>KEY RESULTS: Navitoclax potentiated bendamustine activity in <z:hpo ids='HP_0000001'>all</z:hpo> cell lines tested </plain></SENT>
<SENT sid="5" pm="."><plain>Bendamustine activated p53 in Granta 519 tumours, concurrent with activation of caspase 3 </plain></SENT>
<SENT sid="6" pm="."><plain>Navitoclax also improved responses to bendamustine-rituximab (BR) in a subset of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS AND IMPLICATIONS: Navitoclax in combination with bendamustine and BR is a viable combination strategy for use in the clinic and demonstrated superior efficacy compared with previously reported data for navitoclax plus CHOP and rituximab-CHOP </plain></SENT>
</text></document>